Literature DB >> 26847553

Association between glaucoma eye drops and hyperemia.

Masahide Yanagi1, Yoshiaki Kiuchi2, Yuki Yuasa2, Tsuyoshi Yoneda3, Tamaki Sumi3, Yasuhiro Hoshikawa4, Masahiko Kobayashi4, Atsuki Fukushima3.   

Abstract

PURPOSE: We used an image analysis software program to quantitatively investigate conjunctival injection in patients treated with eye drops for glaucoma.
METHODS: We compared 169 patients (89 men and 80 women) with a diagnosis of glaucoma. Photographs of the conjunctiva were taken on the temporal side of each patient's right eye using a slit lamp. We determined the mean pixel frequencies of the conjunctival blood vessels from the photographs.
RESULTS: The ocular hyperemia of the patients being treated with prostaglandins was more severe than that of the patients being treated with beta-blockers or no eye drops. In multiple comparisons of each of the eye drops, the control group had a significantly lower degree of hyperemia than did the patients being treated with each of the various prostaglandin analogs (latanoprost, travoprost, tafluprost, and bimatoprost). Among the patients receiving prostaglandin, the percentage of those with hyperemia was highest in the bimatoprost users, followed in order by the travoprost, latanoprost, and tafluprost users. However, no significant differences were found among the different prostaglandin analogs in terms of the percentage of patients with hyperemia.
CONCLUSION: Our software program may be useful for evaluating the hyperemic effects of eye drops used for glaucoma. The particular type of prostaglandin analog seems to determine the level of conjunctival hyperemia during ocular hypotensive medical treatment.

Entities:  

Keywords:  Conjunctival injection; Eye drops; Glaucoma; Hyperemia

Mesh:

Substances:

Year:  2016        PMID: 26847553     DOI: 10.1007/s10384-016-0426-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  25 in total

1.  Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.

Authors:  Richard A Lewis; Gregory J Katz; Mark J Weiss; Theresa A Landry; Jaime E Dickerson; John E James; Steven Y Hua; E Kenneth Sullivan; Dawnelle B Montgomery; David T Wells; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2007-01       Impact factor: 2.503

2.  Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.

Authors:  Enyr S Arcieri; Alessandro Santana; Fabiano N Rocha; Gustavo L Guapo; Vital P Costa
Journal:  Arch Ophthalmol       Date:  2005-02

3.  A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.

Authors:  Hiroshi Kobayashi; Kaori Kobayashi
Journal:  J Glaucoma       Date:  2011-01       Impact factor: 2.503

Review 4.  Treatment of glaucoma.

Authors:  L L Remis; D L Epstein
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

5.  Automated hyperemia analysis software: reliability and reproducibility in healthy subjects.

Authors:  Tsuyoshi Yoneda; Tamaki Sumi; Ayako Takahashi; Yasuhiro Hoshikawa; Masahiko Kobayashi; Atsuki Fukushima
Journal:  Jpn J Ophthalmol       Date:  2011-12-01       Impact factor: 2.447

6.  Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.

Authors:  J García-Feijoo; J M Martínez-de-la-Casa; A Castillo; C Méndez; A Fernández-Vidal; J García-Sánchez
Journal:  Curr Med Res Opin       Date:  2006-09       Impact factor: 2.580

7.  Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma.

Authors:  Mei-Ju Chen; Yen-Cheng Chen; Ching-Kuang Chou; Wen-Ming Hsu
Journal:  J Ocul Pharmacol Ther       Date:  2006-12       Impact factor: 2.671

8.  A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.

Authors:  S Parmaksiz; N Yüksel; V L Karabas; B Ozkan; G Demirci; Y Caglar
Journal:  Eur J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.597

9.  Vasoconstrictive effect of topical timolol on human retinal arteries.

Authors:  X D Martin; P A Rabineau
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

10.  Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study.

Authors:  David S Friedman; Steven R Hahn; Laurie Gelb; Jason Tan; Sonali N Shah; Elizabeth E Kim; Thom J Zimmerman; Harry A Quigley
Journal:  Ophthalmology       Date:  2008-03-05       Impact factor: 12.079

View more
  7 in total

1.  Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials.

Authors:  Jo-Hsuan Wu; Sheng-Nan Chang; Takashi Nishida; Bo-I Kuo; Jou-Wei Lin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-07       Impact factor: 3.117

Review 2.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

3.  The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study.

Authors:  Hideaki Okumichi; Yoshiaki Kiuchi; Tetsuya Baba; Takashi Kanamoto; Tomoko Naito; Shunsuke Nakakura; Hitoshi Tabuchi; Hiroki Nii; Chie Sueoka; Yosuke Sugimoto
Journal:  Clin Ophthalmol       Date:  2017-06-21

4.  Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.

Authors:  Emi Sakamoto; Waka Ishida; Tamaki Sumi; Tatsuma Kishimoto; Kentaro Tada; Ken Fukuda; Tsuyoshi Yoneda; Hajime Kuroiwa; Etsuko Terao; Yasuko Fujisawa; Shunsuke Nakakura; Koji Jian; Hideaki Okumichi; Yoshiaki Kiuchi; Atsuki Fukushima
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

5.  Short-Term Effects of Different Types of Anti-Glaucoma Eyedrop on the Sclero-Conjunctival Vasculature Assessed Using Anterior Segment OCTA in Normal Human Eyes: A Pilot Study.

Authors:  Tadamichi Akagi; Yoko Okamoto; Takanori Kameda; Kenji Suda; Hideo Nakanishi; Masahiro Miyake; Hanako Ohashi Ikeda; Tatsuya Yamada; Shin Kadomoto; Akihito Uji; Akitaka Tsujikawa
Journal:  J Clin Med       Date:  2020-12-11       Impact factor: 4.241

6.  Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data.

Authors:  Yunjeong Jang; Donghyun Jee; Donghwan Lee; Nam-Kyong Choi; SeungJin Bae
Journal:  Int J Environ Res Public Health       Date:  2021-04-13       Impact factor: 3.390

7.  Characteristic Assessment of Angiographies at Different Depths with AS-OCTA: Implication for Functions of Post-Trabeculectomy Filtering Bleb.

Authors:  Man Luo; Yingting Zhu; Hui Xiao; Jingjing Huang; Jin Ling; Haishun Huang; Yiqing Li; Yehong Zhuo
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.